Proactive Consultation by a Clinical Pathologist Prevents Diagnostic Delay in Hematological Malignancies.
نویسندگان
چکیده
BACKGROUND Diagnostic difficulties in hematological malignancies may lead to unacceptably prolonged help-seeking to diagnostic interval as well as increased complications and poor outcomes. Proactive consultation by a clinical pathologist (PCCP) may help clinical diagnosis and therapeutic strategy. Hence, the aim of this investigation was to evaluate the effect of PCCP on the help-seeking to diagnostic interval in hematological cancer cases. MATERIALS AND METHODS From January to November, 2015, abnormal results of hematological laboratory testing with added laboratory comment were selectively screened out, and patients with such abnormalities in hematological laboratory testing and accompanied laboratory comment with PCCP were enrolled. RESULTS A total of 125 aberrant results of hematological laboratory testing were given with accompanied laboratory comments with PCCP and 40.8% (n=51) of these patient-oriented comments had an effect on clinical diagnosis and therapeutic strategy. Twelve of the subjects belonged to newly diagnosed hematological malignancies with the assistance of PCCP, and the help-seeking to diagnostic interval was also shortened from 42 days to 26 days in chronic lymphoid leukemia (CLL), from 83 days to 11 days in multiple myeloma (MM), and from 128 days to 15 days in myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN). During the monitoring interval, neither complication events nor deaths were reported in the study group. CONCLUSIONS It was seemingly that PCCP prevented diagnostic delay in hematological malignancies via shortening the help-seeking to diagnostic interval, particularly in CLL, MM and MDS/MPN cases. PCCP can be considered to play an essential role in prompt establishment of diagnosis in hematological malignancies for those who newly present.
منابع مشابه
Determination of Serologic and Molecular Prevalence of Hepatitis Type B, C, and G Infections in Patients with Hematological Malignancy in the South of Fars Province, Iran
Background & Objectives: Hepatitis type G virus (HGV) is a flavivirus with RNA genome which has high nucleotide and amino acid similarity with HCV. HGV can infect blood lymphocytes for long period and may have role in inducing or complicating the clinical outcomes in patients with hematological malignancies. Therefore in this study the prevalence of HGV, HCV, and HBV infections were evaluated i...
متن کاملAssociation between Cytochrome P450 2C19 Gene Polymorphisms and Hematological Malignancies in an Iranian Population
Background: Cytochrome P450 2C19 (CYP2C19) is widely involved in the metabolism of some medications. On the other hand, recent studies have shown the contribution of the CYP2C19 polymorphisms to different malignancies. We aimed to investigate the association between CYP2C19 polymorphism and occurrence of hematological malignancies by comparing the phenotype distribution of this enzyme in patien...
متن کاملAntibiotic resistance status and its costs in hematological patients: A two-year analysis
Background: Most frequently, empirical antibiotic therapy is immediately administered for patients with febrile neutropenia (FN). In this study, its aim was to assess the antibiotic resistance status and the cost of antibacterial agents in FN patients associated with hematological malignancies. Methods: The cost of antibacterial agents used in FN episodes in patients with hematologic neoplasms ...
متن کامل[Decipher the 2016 revision of the World Health Organization classification of lymphoid neoplasms].
The European Society of Pathology and the Society for Hematopathology have developed a new World Health Organization (WHO) classification of hematological malignancies. The classification is based on the principle that the classification is a list of entities defined by the combination of morphology, immunophenotype, genetic and clinical features. The WHO classification is a new basis of commun...
متن کاملDiagnostic Evaluation of Hematological Sepsis Score and Presepsin in Neonatal Sepsis
Background: Early detection of neonatal sepsis and categorization of patients based on clinical severity is not yet effectively achieved. Some hematological parameters are used to formulate a hematological scoring system (HSS) and a modified hematological scoring system (MHSS) to diagnose neonatal sepsis. A promising biomarker: Presepsin, or Soluble Cluster of Differentiation 14 SubType (sCD14-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Asian Pacific journal of cancer prevention : APJCP
دوره 17 3 شماره
صفحات -
تاریخ انتشار 2016